Please join us for a special webinar discussion with PROFESSOR GIL ATZMON, University of Haifa Associate Professor of Epigenetics and Genomics in the Faculty of Natural Sciences, and Associate Professor of Medicine and Genetic at Albert Einstein College of Medicine, and DR. DANIELLE GUTMAN, University of Haifa Postdoc Fellow in the Lab of Epigenetics and Genomics, about what we can do to close the gap between a person’s life expectancy and their “healthy” life expectancy.
The discussion will be moderated by MICHAEL ROSEN, Managing Director, Innovation and Research Park and Helix 51 for Rosalind Franklin University and and Member of University of Haifa’s Board of Directors.
Pre-Registration requested.
Upon registration you will receive a confirmation email containing information about joining the webinar.
PROFESSOR GIL ATZMON, an Associate Professor of Epigenetics and Genomics in the Faculty of Natural Sciences, University of Haifa, Israel, and of Medicine and Genetic at Albert Einstein College of Medicine, began his career studying biotechnology at Hebrew University, going on to earn his PhD in population genetics. Professor Atzmon’s focus is in a new and challenging field involving the role of epigenetics in diseases, aging and longevity. The foremost focus of Professor Atzmon’s research career has been the understanding of the association of the whole genome to disease, performance, health, and longevity. To this end, Professor Atzmon and colleagues have established the Israeli Multi-Ethnic Centenarian Study (I-MECS), recruiting healthy, independently living Israeli multi-ethnic people 95 and older to profile them.
DR. DANIELLE GUTMAN, a Postdoc Fellow in the lab of Epigenetics and Genomics of Aging/Longevity headed by Professor Atzmon, has a B.Sc. in Biology and Mathematics, a M.Sc. in Human Biology, and a Ph.D. from University of Haifa. As part of her Ph.D. work under the mentorship of Professor Atzmon, Dr. Gutman worked to establish the I-MECS, recruiting and processing the samples of over 120 participants in 3.5 years. Her PhD characterized the genome and epigenome of exceptionally long-lived individuals from the IMECS cohort and from a larger cohort of Ashkenazi Jews available through the Einstein College of Medicine.
MICHAEL ROSEN is Managing Director, Innovation and Research Park and Helix 51 Incubator for Rosalind Franklin University. Mr. Rosen had his own company, Rosen Bioscience Strategies LLC, a life science economic development consultancy focused on the development of science parks, incubators and eco-systems centered around research-based universities. He has worked extensively with and trained more than 300 university faculty on the creation of bioscience start-ups. Rosen is a member of University of Haifa’s Board of Directors.